AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

We're now just past the midpoint of astronomical winter — that moment marking the midway point between December's winter solstice and March's vernal equinox. That moment took place at 4:11 p.m.

The trend of making features in MIcrosoft Word require an Internet connection is frustrating, but these features still work ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The US Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to treating ...

So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today. Bansal saw no major catalyst could drive the stock up in the near ...